AngioDynamics Reports Positive Growth Amid Challenges Ahead
AngioDynamics Shows Resilience with Strong Performance
AngioDynamics, Inc. (NASDAQ: ANGO) has recently demonstrated remarkable strength in its Med-Tech sector, reporting first-quarter results that exceeded expectations. This level of performance has led the company to increase its fiscal 2026 guidance significantly. Their adaptability in navigating challenges, including tariff impacts, showcases a promising future for the firm.
Analyst Ratings and Price Forecasts
According to analysts from Canaccord Genuity, led by John Young, the outlook for AngioDynamics is bullish. They have maintained a Buy rating on the stock and elevated their price target from $17 to $18, attributing this revised forecast to positive growth indications and anticipated cash flow improvement in the coming fiscal year.
Quarterly Performance Metrics
In the first quarter, AngioDynamics reported a revenue increase of 12.1%, reaching $75.7 million, which surpassed market consensus. This growth was bolstered by a 26.2% surge in Med-Tech sales. The company also achieved a gross margin of 55.3%, which was higher than the expected 52.5%. Although the adjusted earnings per share (EPS) loss of 10 cents slightly fell below forecast, the adjusted EBITDA of $2.2 million was a positive surprise, indicating good operating performance.
Revenue Guidance for Fiscal Year 2026
The management team has updated its revenue guidance for fiscal year 2026, now projecting figures between $308 million and $313 million, marking a healthy growth rate of 14% to 16%. Adjusted EBITDA expectations are also promising, with projections ranging from $6 million to $10 million, and positive cash flow expected during the latter half of the year.
Challenges from Tariffs and Manufacturing Transitions
The company is not without its hurdles. AngioDynamics is facing heightened pressures from tariffs, particularly affecting its Med-Device products manufactured in Costa Rica, which are subject to a 15% tariff. Furthermore, production in Italy and Poland also faces tariff-related costs, potentially imposing an additional $4 million to $6 million annual impact on the company’s financials.
Key Product Performances
Growth in Mechanical Thrombectomy
The Mechanical Thrombectomy segment has significantly outperformed expectations, with revenue soaring by 41.2% year-over-year, reaching $11.3 million. The success of AngioVac and AlphaVac has been pivotal, and analysts believe that expanding cross-selling opportunities coupled with an enhanced sales force will sustain this growth.
Auryon and NanoKnife Achievements
The Auryon platform reported $16.5 million in revenue, signaling a 20.1% increase year-over-year, and surpassed analyst expectations. The growth is driven by increased adoption in outpatient labs and hospitals, alongside international sales benefitting from recent CE mark approval. Meanwhile, the NanoKnife product line achieved revenue of $6.4 million, growing by 26.7% compared to the previous year; this growth is particularly noteworthy as it has yet to benefit from the upcoming CPT 1 code effective January 1, 2026.
Financial Health and Future Projections
At the end of the quarter, AngioDynamics boasted a robust cash position with $38.8 million on hand, no outstanding debt, and unrestricted access to a $25 million revolving credit facility. While the company anticipates approximately $3 million in cash burn in the second quarter, management is optimistic about achieving cash flow positive status in the latter half of the fiscal year.
Analyst Projections
Canaccord's revised forecasts suggest that AngioDynamics could reach revenues of $310.9 million in fiscal year 2026 and $325.1 million in fiscal year 2027. These estimates represent slight adjustments in expectations, with the anticipated adjusted EPS losses projected at 33 cents for fiscal year 2026 and 4 cents for fiscal year 2027, compared to earlier estimates of a 29-cent loss and a 1-cent profit.
Current Stock Performance
As of the latest trading session, ANGO shares experienced a slight uptick of 2.04%, trading at approximately $11.98. Investors remain optimistic about the company’s capability to navigate its current challenges while accomplishing significant growth milestones.
Frequently Asked Questions
What is AngioDynamics' stock ticker?
The stock ticker for AngioDynamics is ANGO.
What were AngioDynamics' Q1 revenue figures?
The Q1 revenue for AngioDynamics was $75.7 million, which reflects a 12.1% increase compared to the previous period.
What challenges is AngioDynamics facing?
AngioDynamics is facing challenges from tariffs impacting manufacturing costs and revenue projections.
What products are contributing to AngioDynamics' growth?
Key products driving growth include AngioVac, AlphaVac, Auryon, and NanoKnife, each showing significant revenue increases.
What are the future revenue projections for AngioDynamics?
For fiscal year 2026, AngioDynamics projects revenues between $308 million and $313 million.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
